桑拿小姐

About BrightGene

About

BrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special generic APIs and FDFs with primary strategic focus on the regulated market. 


We have an exciting and very promising innovative pipeline including immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumor, novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastasis.



In parallel, we have also developed a special generic pipeline of extremely challenging molecules like Eribulin, Trabectedin, Fondaparinux, Caspofungin and non-biological macromolecules such as Ferumoxytol and Ferric pyrophosphate citrate, also we have developed ADC cytotoxic payloads, like Maytansinoids, Auristatins, and Calicheamicin.

Aim at regulated market, BrightGene has cGMP compliance factories, and has got approval from USFDA, EU, PMDA, KFDA and CFDA.

We pride ourselves in exceptional R&D capability and robust project execution. Combining high productivity and cost-effective resources, along with unmatched regulatory and technical know-how, BrightGene is uniquely positioned to compete in the global pharmaceutical industry, particularly the fast growing specialty pharmaceutical sector.

桑拿小姐 海南环岛赛 189比分直播 即时比分体球手机 比分网篮球比分 足彩半全场 广东十一选五 球探网即时比分007 电竞比分网即时比分 188网球比分直播 吉林快3 体球网即时赔率 韩国快乐8 广东十一选五 奥迅球探网足球指数 棒球比分翻译 四川时时彩